Literature DB >> 10998424

Loss of Ikappa B-beta is associated with prolonged NF-kappa B activity in human glial cells.

E Bourke1, E J Kennedy, P N Moynagh.   

Abstract

Nuclear factor-kappaB (NF-kappaB) is an inducible transcription factor central in the regulation of expression of a wide variety of genes and synthesis of several proteins involved in the generation of the immune response and inflammatory processes. In resting cells, NF-kappaB is maintained in an inactive state through cytoplasmic retention by IkappaB inhibitors. Stimulation of cells with a wide variety of inducers results in proteolytic degradation of these IkappaB proteins, leading to activation of NF-kappaB. The present study shows that interleukin-1 (IL-1) causes persistent activation of NF-kappaB in glial cells. Stimulation with IL-1 also causes rapid but transient degradation of IkappaB-alpha and IkappaB-epsilon. However, NF-kappaB remains active even after these IkappaB isoforms have returned to control levels. In contrast, the IkappaB-beta isoform fails to reappear following its initial degradation by IL-1, coincident with sustained activation of NF-kappaB. In addition, in vivo overexpression of the various IkappaB isoforms revealed that IkappaB-beta is the only isoform that has the ability to inhibit IL-1-induced NF-kappaB-driven transcription. The findings also suggest that the inability of IkappaB-alpha and IkappaB-epsilon to modulate NF-kappaB activity is due to their modification in vivo. These findings indicate that IkappaB-beta is the key regulator of the activity of NF-kappaB in human glial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998424     DOI: 10.1074/jbc.M007693200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production.

Authors:  Yushi Bai; Hiroki Onuma; Xu Bai; Alexander V Medvedev; Mary Misukonis; J Brice Weinberg; Wenhong Cao; Jacques Robidoux; Lisa M Floering; Kiefer W Daniel; Sheila Collins
Journal:  J Biol Chem       Date:  2005-03-09       Impact factor: 5.157

2.  Astragalus polysaccharide attenuates lipopolysaccharide-induced inflammatory responses in microglial cells: regulation of protein kinase B and nuclear factor-κB signaling.

Authors:  Tao Luo; Jian Qin; Min Liu; Jun Luo; Fang Ding; Mingling Wang; Limin Zheng
Journal:  Inflamm Res       Date:  2015-02-11       Impact factor: 4.575

3.  In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation.

Authors:  Bryan D Griffin; Paul N Moynagh
Journal:  Biochem J       Date:  2006-11-15       Impact factor: 3.857

4.  Gamma-aminobutyric acid inhibits synergistic interleukin-6 release but not transcriptional activation in astrocytoma cells.

Authors:  Joseph D Roach; Grant T Aguinaldo; Kaumudi Jonnalagadda; Francis M Hughes; Bryan L Spangelo
Journal:  Neuroimmunomodulation       Date:  2008-08-05       Impact factor: 2.492

Review 5.  The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain.

Authors:  Paul N Moynagh
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

6.  IκBβ attenuates angiotensin II-induced cardiovascular inflammation and fibrosis in mice.

Authors:  Shanqin Xu; Hui Zhi; Xiuyun Hou; Richard A Cohen; Bingbing Jiang
Journal:  Hypertension       Date:  2011-06-06       Impact factor: 10.190

7.  RelA/p65 regulation of IkappaBbeta.

Authors:  Erin Hertlein; Jingxin Wang; Katherine J Ladner; Nadine Bakkar; Denis C Guttridge
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

8.  Production of inflammatory mediators by renal epithelial cells is insensitive to glucocorticoids.

Authors:  Simone de Haij; Andrea M Woltman; Astrid C Bakker; Mohamed R Daha; Cees van Kooten
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

9.  IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo.

Authors:  Melanie Scheibel; Bettina Klein; Heidrun Merkle; Manon Schulz; Ralph Fritsch; Florian R Greten; Melek C Arkan; Günter Schneider; Roland M Schmid
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

10.  Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients.

Authors:  Maria Chiara Maiuri; Daniela De Stefano; Guido Mele; Simona Fecarotta; Luigi Greco; Riccardo Troncone; Rosa Carnuccio
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.